Renaissance Capital logo

CATB News

Lipid drug delivery: Sancilio Pharmaceuticals files for an $86 million IPO

Sancilio Pharmaceuticals Company, which markets, licenses and develops products based on its lipid drug delivery technology, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Riviera Beach, FL-based company, which was founded in 2006 and booked $22 million in revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq...read more

US IPO Weekly Recap: Year's hottest deal pops 186% in year's most active week with 13 IPOs

Things just got Seres in the IPO market. Thirteen companies went public this past week, more than any week since October 2014. Seres Therapeutics skyrocketed 186% on its debut - the highest first-day pop since January 2014. The thirteen IPOs raised $1.9 billion, less than expected because 70%...read more

Catabasis Pharmaceuticals prices IPO at $12, below the range

Catabasis Pharmaceuticals, which is developing combined therapies for Duchenne muscular dystrophy and high cholesterol, raised $60 million by offering 5 million shares (upsized from 4.3 million shares) at $12, below the range of $13 to $15. Catabasis Pharmaceuticals plans to list on the NASDAQ under the symbol CATB. Catabasis Pharmaceuticals initially filed confidentially on...read more

Week ahead: As many as 17 IPOs could price during the week of June 22

TRU

17 companies are on the calendar to go public this week and raise $2.5 billion. It should be the year's most active week in the IPO market; the second busiest week saw 10 IPOs in January. Investors have plenty of options this week, so expect IPO investors to demand discounts on some of the less hot...read more